Cost-effectiveness of rHu-EPO in oncology

摘要: Approximately 13 million Americans are diagnosed with cancer every year and the various therapies they receive often as physically trying itself [2, 26]. Pain, nausea, infection, anemia common debilitating side effects experienced by many patients undergoing chemotherapy radiotherapy. As attention has turned toward improving quality of life for treatment, advances have been made in managing these [14, 27, 33]. However, a treatment beyond traditional blood transfusions remained elusive until introduction recombinant human erythropoietin “rHu-EPO (epoetin alfa)”, which it possible to aggressively treat [10, 13, 14, 18, 22–24, 31].